vanadates has been researched along with tallimustine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Capolongo, L; Ciomei, M; Geroni, C; Grandi, M; Melegaro, G; Pastori, W; Pennella, G | 1 |
Dvilansky, A; Kafka, M; Nathan, I; Parola, AH; Zamai, M; Zou, JP | 1 |
2 other study(ies) available for vanadates and tallimustine
Article | Year |
---|---|
Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Distamycins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia L1210; Mice; Neoplasm Proteins; Nitrogen Mustard Compounds; Phosphorylation; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Sensitivity and Specificity; Tumor Cells, Cultured; Tyrosine; Vanadates | 1995 |
Distamycin-A derivatives potentiate tumor-necrosis-factor activity via the modulation of tyrosine phosphorylation.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Transformed; Distamycins; Dose-Response Relationship, Drug; Drug Synergism; Humans; Mice; Nitrogen Mustard Compounds; Protein Tyrosine Phosphatases; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vanadates | 1997 |